1 Competition and diversity determine vaccine impact on antibiotic resistance

2 evolution

- 3
- 4 Nicholas G. Davies^{1*}, Stefan Flasche¹, Mark Jit^{1,2}, Katherine E. Atkins^{1,3}
- 5
- 6 1. Centre for Mathematical Modelling of Infectious Diseases; Vaccine Centre; and
- 7 Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical
- 8 Medicine, London, UK.
- 9 2. Modelling and Economics Unit, Public Health England, London, UK.
- 10 3. Centre for Global Health, Usher Institute of Population Health Sciences and
- 11 Informatics, The University of Edinburgh, Edinburgh, UK.
- 12 * Corresponding author. Address: Department of Infectious Disease Epidemiology,
- 13 Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical
- 14 Medicine, Keppel Street, London WC1E 7HT, United Kingdom. Phone: +44 20 7927
- 15 2880. E-mail: <u>nicholas.davies@lshtm.ac.uk</u>.
- 16
- 17 **One sentence summary:** Competition and diversity are key to antibiotic resistance
- 18 evolution and determine whether vaccines will prevent or increase resistant infections.

19 Bacterial vaccines can protect recipients from contracting potentially antibiotic-20 resistant infections. But by altering the selective balance between sensitive and 21 resistant strains, vaccines may also help suppress—or spread—antibiotic 22 resistance among unvaccinated individuals. Predicting the outcome requires 23 knowing the drivers of resistance evolution. Using mathematical modelling, we 24 identify competition and diversity as key mediators of resistance evolution. 25 Specifically, we show that the frequency of penicillin resistance in *Streptococcus* 26 pneumoniae (pneumococcus) across 27 European countries can be explained by 27 between-host diversity in antibiotic use, heritable diversity in pneumococcal 28 carriage duration, or within-host competition. We use our calibrated model to 29 predict the impact of universal pneumococcal vaccination upon the prevalence of 30 carriage, incidence of disease, and frequency of resistance for *S. pneumoniae*. The 31 relative strength and directionality of competition between resistant and 32 sensitive pneumococcal strains determines whether vaccination promotes, 33 inhibits, or has little effect on the evolution of antibiotic resistance. Finally, we 34 find that differences in overall bacterial transmission and carriage alter 35 predictions, suggesting that evidence-based policies for managing resistance with 36 vaccines must be tailored to both pathogen and setting.

37

38 In an age of widespread antibiotic resistance, there is growing interest in using vaccines 39 to prevent bacterial infections that would otherwise call for treatment with antibiotics 40 (1–4). This interest arises for two main reasons: first, vaccines are effective against both 41 antibiotic-resistant and antibiotic-sensitive bacteria; and second, successful prophylaxis 42 removes the need for a course of antibiotic therapy that might promote more resistance 43 (2–5). Over the past two decades, the use of pneumococcal conjugate vaccines (PCVs) 44 has seemingly borne out these advantages. Administering PCVs to young children has 45 substantially reduced disease caused by *S. pneumoniae* (5–8)—a common asymptomatic coloniser of the nasopharynx which can cause pneumonia, meningitis and other 46 47 infections when invasive—and has decreased demand for antibiotic therapy, largely by 48 reducing cases of otitis media (5, 9). But because PCV formulations target only a fraction 49 of the ~100 known pneumococcal serotypes, the niche vacated by PCV-targeted serotypes has been filled by non-vaccine serotypes, and overall pneumococcal carriage 50 51 has rebounded to pre-vaccine levels (10, 11). Concomitantly, the incidence of infections

52 attributed to non-vaccine serotypes (12) and the proportion of non-vaccine-type

53 infections exhibiting antibiotic resistance (5, 13) have risen in many settings. Concern

54 over serotype replacement—along with the high cost of PCV manufacturing—has

55 spurred the development of "universal" whole-cell or protein-based pneumococcal

- 56 vaccines protecting against all serotypes, some of which are now in early-stage clinical
- 57 trials (14).
- 58

59 However, it is unclear how universal vaccination may itself impact upon the evolution of 60 antibiotic resistance in *S. pneumoniae*, which is a concern given that vaccination is 61 unlikely to eliminate pneumococcal disease (15). Mathematical models can be used to 62 generate predictions from nonlinear transmission dynamics (16, 17), but existing 63 models focus on serotype-specific vaccines and, even then, disagree over the expected 64 impact of vaccination on resistance evolution (18–24). Comparing and interpreting the 65 results of these models is hampered by the fact that none starts from a position of 66 recapitulating large-scale empirical patterns of antibiotic resistance. The main challenge 67 in replicating these patterns lies in identifying the mechanisms that maintain long-term 68 coexistence between sensitive and resistant pneumococcal strains across a wide range of antibiotic treatment rates, like those seen across Europe and the United States (25, 69 70 26). Robust predictions of the long-term impact of vaccination on resistant 71 pneumococcal disease require a mechanistic understanding of these patterns. 72 73 Results 74 75 **Competition and diversity maintain stability in resistance evolution.** A model must 76 be able to explain the current burden of an infectious disease before it can be used to 77 robustly predict the impact of interventions for managing that disease. Across Europe, 78 the frequency of antibiotic resistance among isolates from pneumococcal infections 79 shows two salient features for models to recapitulate (Supplementary Fig. 1). One is 80 spatial: the frequency of penicillin non-susceptibility varies between countries, and is higher in countries where more penicillin is consumed (27). The other is temporal: 81 82 although in individual countries resistance fluctuates from year to year, the overall 83 frequency across Europe of penicillin non-susceptibility in pneumococcal isolates has 84 remained steady at roughly 12% since consolidated records began in 2005 (28). These

observations contradict simple models of resistance evolution, which predict that
intermediate frequencies of resistance cannot be stably maintained in the long term:
that is, either sensitive strains will competitively exclude resistant strains, or resistant
strains will competitively exclude sensitive strains, unless there is some mechanism
maintaining coexistence between them (25, 29).

91 By conducting a literature search, we identify nine such mechanisms (25, 26, 30–41) 92 that fall into two broad classes. In one class, coexistence is maintained by 93 environmental or genetic diversity that prevents resistant and sensitive strains from 94 completely overlapping in competition. In the other class, competition between 95 resistant and sensitive strains is itself the stabilising factor that maintains coexistence, 96 because resistant and sensitive strains exhibit alternative competitive phenotypes that 97 afford strains a competitive advantage when rare, thus promoting negative frequency-98 dependent selection for resistance. Thus, diversity and competition are two key forces 99 maintaining stability in resistance evolution. Of the nine identified mechanisms, we find 100 that four are biologically plausible for maintaining coexistence in *S. pneumoniae* (Table 101 1).

102

103 Four models of resistance evolution. To compare these four mechanisms, we embed 104 each in a shared model framework of person-to-person transmission of nasopharyngeal 105 pneumococcal carriage. This framework tracks the country-specific frequency of 106 resistance in pneumococci circulating among children under five years old, the age 107 group that drives the majority of pneumococcal transmission and disease (42, 43). We 108 assume that each individual makes effective contact with another random individual at 109 rate β , thereby potentially acquiring a strain (either sensitive or resistant) carried by 110 the contacted person. With probability *c*, resistant strains fail to transmit, where *c* 111 represents the transmission cost of resistance (44, 45). A carrier naturally clears all strains at rate u, and is exposed to antibiotic therapy at a country-specific rate τ , which 112 113 clears the host of sensitive strains only. We assume this treatment rate is independent 114 of carriage status (46) and we do not explicitly track disease progression in hosts. 115 Under the "Treatment diversity" and "Pathogen diversity" models, coexistence is 116

117 maintained because diversity among hosts or among pathogens prevents resistant and

118 sensitive strains from fully overlapping in competition. In the "Treatment diversity" 119 model (Fig. 1a), heterogeneity in the consumption of antibiotics between host subpopulations within a country maintains coexistence (25, 34, 35). These 120 121 subpopulations could correspond to geographical regions, socioeconomic strata, host 122 age and risk classes, or a combination of these. Provided that transmission between 123 high-consumption (resistance-promoting) and low-consumption (resistance-inhibiting) 124 subpopulations is not too frequent, an intermediate frequency of resistance can be 125 maintained across the whole population. The key parameters governing coexistence in 126 this model are κ, the variability in antibiotic consumption between subpopulations, and 127 g, the relative rate at which within-country contact is made within subpopulations 128 rather than between them.

129

130 In the "Pathogen diversity" model (Fig. 1b), pneumococci are divided into subtypes ("D-131 types" (38)) that vary in their mean duration of natural carriage. All else equal, the D-132 type with the longest carriage duration would be expected to competitively exclude all 133 other strains; the model assumes that diversifying selection acting on the D-type locus 134 keeps all subtypes in circulation. What D-types correspond to is not explicitly specified by this model, but one candidate is serotype variation. For example, if antigenic 135 136 diversity is promoted by host acquired immunity to capsular serotypes, and serotypes 137 tend to differ in their intrinsic ability to evade clearance by the immune system, then 138 intermediate resistance can be maintained because selection for resistance tends to be 139 greater in strains that have a longer duration of carriage (38). Long-lasting serotypes 140 will tend to evolve resistance, while shorter-lived serotypes will tend not to—a pattern 141 observed in *S. pneumoniae* (38) and reproduced by this model (Supplementary Fig. 2). 142 The parameters governing coexistence in this model are *a*, the strength of diversifying 143 selection on the D-type locus, and δ , the variability between subtypes in clearance rate. 144

145 Under the "Treatment competition" and "Growth competition" models, coexistence is 146 maintained because of competition between sensitive and resistant strains. In these 147 models, hosts can be co-colonised by multiple strains, but which strain a co-colonised 148 host transmits to other potential hosts is determined by within-host competition 149 between strains (26). The "Treatment competition" model (Fig. 1c) assumes that 150 antibiotic therapy mediates within-host competition, such that when a co-colonised

151 host takes antibiotics (*i.e.*, at rate τ), the sensitive strains are cleared and only the 152 resistant strains are transmitted to other hosts. The "Growth competition" model (Fig. 1d) has both treatment-mediated and growth-mediated competition: while in the 153 154 presence of antibiotics, resistant strains still outcompete co-colonising sensitive strains, 155 in the absence of antibiotics, sensitive strains gradually outcompete co-colonising 156 resistant strains at rate b. We assume that there is no transmission cost of resistance in 157 this latter model (*i.e.*, c = 0); instead, the within-host growth advantage b of sensitive 158 strains accounts for the cost of resistance. In these competition models, resistant strains 159 have an advantage in antibiotic-mediated competition, while sensitive strains have an 160 advantage in growth-mediated competition. These alternative forms of within-host 161 competition can both promote coexistence because rare strains can more consistently 162 exploit a competitive advantage over common strains, thus creating negative frequency-163 dependent selection for resistance (26). The key parameter governing coexistence in 164 these two models is k, the relative rate of co-colonisation compared to primary 165 colonisation.

166

In all four models, we assume that contact between individuals is assortative by 167 168 country, such that with probability *f*, contact is with a random person from the same country, and with probability 1 – *f*, contact is with a random person from any country. 169 170 We implement these models using systems of ordinary differential equations. All four models (25, 26, 38) are structurally neutral (25, 29), meaning that any coexistence 171 172 exhibited by the models is accounted for by the specified biological mechanism rather 173 than by any bias in the logical structure of the model that generates coexistence "for 174 free". Additionally, while the within-host competition models capture co-colonisation 175 using a simplified subset of only 2 "mixed-carriage" states (S_R and R_S, Fig. 1a&b), we 176 have previously shown (26) that this is equivalent to a more complex individual-based 177 model with an arbitrary number of mixed-carriage states. 178

All four models reproduce observed patterns of resistance. The European Centre
for Disease Prevention and Control (ECDC) monitors antibiotic consumption and
resistance evolution across European countries (*13, 28*). These data capture a natural
experiment in resistance evolution: for each monitored drug and pathogen, each
country reports a different rate of antibiotic consumption in the community and

184 exhibits a different frequency of resistance among invasive bacterial isolates. By fitting 185 models to this multi-country data set, we can potentially rule out models that cannot 186 reproduce the large-scale patterns that are observed. We use Bayesian inference to fit 187 the model-predicted equilibrium frequency of resistance to the reported frequency of 188 penicillin non-susceptibility in S. pneumoniae across 27 European countries, assuming a 189 50% carriage prevalence (11, 42) and a carriage duration of 47 days (47, 48) in children 190 under five years old. We begin by assuming that countries only differ by their reported 191 treatment rate—where we define a treatment course as equivalent to z = 5 defined daily 192 doses of penicillin—with other model parameters shared across countries.

193

194 Strikingly, each model fits equally well to the empirical relationship between resistance

and antibiotic use (all model WAICs are similar; Fig. 2a) and recovers plausible

196 posterior parameter distributions (Fig. 2b). That is, the empirical data do not

197 distinguish between the four alternative mechanisms of resistance evolution we have

198 identified. Later, we relax the assumption that only the treatment rate varies between

199 countries, allowing us to capture additional between-country variation in resistance not

200 explained by population-wide penicillin consumption.

201

202 Competition and diversity determine the impact of vaccination on resistant

203 disease. To determine the impact of universal vaccination on pneumococcal disease, we 204 consider three outcomes. The first is the impact of the vaccine upon the prevalence of 205 pneumococcal carriage. The second is the vaccine impact upon the frequency of 206 penicillin resistance among circulating pneumococcal strains remaining after 207 vaccination. The third is the impact of the vaccine upon the prevalence of resistant 208 pneumococcal carriage—*i.e.*, the prevalence of carriage multiplied by the frequency of 209 penicillin resistance. Since all four models are equally capable of recapitulating 210 observed patterns of penicillin resistance in S. pneumoniae, our aim is to determine 211 whether the mechanism of resistance evolution—competition or diversity—matters 212 when forecasting the impact of interventions for managing resistance.

213

214 We consider two alternative vaccines: an "acquisition-blocking" vaccine, which prevents

215 carriage from being established with probability ϵ_a , and a "clearance-accelerating"

216 vaccine, which shortens the duration of carriage by a fraction ϵ_c . Both vaccines reduce

217 pneumococcal transmission through alternative modes of host immunity that might be 218 elicited by a whole-cell or protein-based universal pneumococcal vaccine. Analogously 219 to naturally-acquired serotype-independent pneumococcal immunity (49), the 220 protective effect of whole-cell vaccines manifests as accelerated clearance (50); it is 221 unclear whether protein-based vaccines would block pneumococcal acquisition, like 222 PCVs, or accelerate clearance (51). We refer to ε_a or ε_c as the vaccine efficacy, and for 223 simplicity, we assume that all children under five years old have vaccine protection, as 224 would be established by an infant vaccination programme rolled out across Europe. In 225 order to compare these vaccines with an alternative intervention of antibiotic 226 stewardship, we also evaluate the impact of reducing the rate of penicillin prescribing

- 227 by a fraction ε_s .
- 228

229 We find that both vaccines have a similar impact upon carriage prevalence, regardless 230 of whether competition or diversity maintains stability in resistance evolution (Fig. 3a). 231 Specifically, as the vaccine efficacy ε_a or ε_c increases, carriage decreases, with the 232 elimination of pneumococcal carriage occurring at a vaccine efficacy between 50 and 233 60%. Reducing antibiotic prescribing moderately increases pneumococcal carriage, 234 such that carriage prevalence increases to approximately 54% across all countries 235 when penicillin prescribing is eliminated completely.

236

237 However, the mechanism of resistance evolution has a substantial impact upon whether 238 vaccines increase or decrease the frequency of resistance in *S. pneumoniae* in the long 239 term (Fig. 3b). In the "Treatment diversity" and "Pathogen diversity" models, the 240 acquisition-blocking vaccine has relatively little impact upon the frequency of 241 resistance, because administering a universal pneumococcal vaccine to all individuals 242 does not substantially alter the distribution of antibiotic use or of heritable variation in 243 clearance rates. By contrast, in the within-host competition models, vaccination has a 244 substantial impact upon resistance evolution because by reducing pneumococcal 245 circulation, vaccines decrease the rate at which strains encounter each other within 246 hosts, and hence strongly decrease competition between pneumococcal strains. 247 Specifically, the acquisition-blocking vaccine selects strongly against resistance in the 248 "Treatment competition" model: since antibiotic-mediated within-host competition 249 benefits the resistant strain in this model, the vaccine works against this competitive

advantage and therefore inhibits resistance. Conversely, in the "Growth competition"

251 model, growth-mediated competition benefits the sensitive strain, and so by reducing

- 252 competition, vaccination tends to promote resistance. These results expand upon our
- 253 previous finding that the rate of co-colonisation modulates resistance evolution through
- its impact upon within-host competition (26).
- 255
- 256 The clearance-accelerating vaccine exhibits similarly divergent impacts across
- 257 mechanisms of resistance evolution. However, compared with the acquisition-blocking
- vaccine, it also has an additional resistance-inhibiting effect across all models, because a
- shorter duration of carriage—whether natural or vaccine-induced—selects against
- 260 resistance (38). This suggests that vaccines that accelerate natural clearance have a
- 261 particular potential for managing resistant infections.
- 262

263 Reducing the rate of penicillin prescribing selects against resistance, as expected,

- 264 exhibiting a similar impact across all four models.
- 265

The impact on resistant carriage (Fig. 3c), which combines changes in the prevalence of carriage and changes in the frequency of resistance, can be treated as a proxy for the incidence of resistant infections. Overall, under the "Growth competition" model, vaccination at intermediate efficacy is expected to increase the rate of resistant carriage, and hence the number of cases of resistant disease. In other models, vaccination always reduces resistant carriage, particularly under the "Treatment competition" model. A summary of the strongest vaccine impacts is shown in Fig. 3d.

273

274 Evidence to inform policy and vaccine trials. For vaccines to be considered an 275 efficient means of controlling resistant infections, they must compare favourably to 276 existing interventions, such as reducing inappropriate antibiotic use (52). The UK 277 government has recently announced an initiative to reduce antibiotic consumption by 278 15% by the year 2020 (52). Our models predict that a 15% reduction in primary-care 279 penicillin consumption would reduce carriage of penicillin-non-susceptible 280 pneumococci from 6% to 3%. The vaccine efficacy required to yield the same effect 281 varies considerably depending upon the mechanism of resistance evolution (Fig 4a); for 282 example, the required vaccine efficacy is lowest under the "Treatment competition"

model ($\epsilon_a = 11\%$; $\epsilon_c = 7\%$), and highest under the "Growth competition" model ($\epsilon_a = 52\%$; $\epsilon_c = 50\%$). A full comparison of vaccine and stewardship interventions would require accounting for the economic cost of vaccines versus antibiotics, the wider range of resistant pathogens that would be targeted by restrictions on antibiotic use, and any potential increase in pathogen circulation that might be brought about by inadvertent decreases in appropriate antibiotic use.

289

290 In randomized controlled trials of pneumococcal conjugate vaccines, resistance-related 291 endpoints have routinely been evaluated over a follow-up period of between 6 months 292 and 3.5 years after vaccination (53, 54). If vaccine-induced changes in resistance 293 evolution unfold over a considerably longer timescale, similarly-designed trials may not 294 appropriately capture vaccine impact on resistance. Indeed, we find that it can take 5-295 10 years for the full effects of resistance evolution to be seen (Fig. 4b), and that short-296 term drops in resistance can be reversed—or even give way to increased resistance—in 297 the long term. Moreover, a trial in which vaccination is not offered to a substantial 298 fraction of the population would not capture the full impact of reduced pneumococcal 299 circulation, which is what drives competition-mediated changes in resistance in our 300 models. Finally, our analysis assumes that vaccines are administered to all recipients 301 simultaneously. In a real-world setting where vaccination would be rolled out gradually. 302 the full effect of vaccination could take even longer to observe.

303

304 The impact of vaccination at a national level varies depending upon the treatment rate 305 in a given country. Focusing on the specific outcome of childhood pneumococcal 306 pneumonia cases, we find that while interventions have a consistent impact from 307 country to country on the total pneumonia case rate, the impact on resistant pneumonia 308 cases is greatest in those countries where antibiotic use, and hence resistance, is highest 309 (Fig. 4c). We focus on resistant carriage, but the realised health benefits of any 310 intervention targeting both resistant and sensitive strains will depend upon the relative 311 health burdens of susceptible versus non-susceptible *S. pneumoniae* infections, which is 312 an area of ongoing research (55). 313

314 Vaccination in a high-burden setting. High prevalences of carriage, disease, and
315 resistance are often observed in low-income settings, and this may substantially alter

316 predictions of vaccine impact. As an illustrative example, a 90% pneumococcal carriage

317 rate, with 81% of isolates resistant to penicillin, has been observed among children

- 318 under five years old in western Kenya (56). This may be partly attributable to a longer
- 319 average duration of carriage in this setting, as a 71-day mean duration of natural
- 320 pneumococcal carriage has been measured in Kilifi, eastern Kenya (57).
- 321

322 To model a similar high-burden setting, we adjust model parameters estimated from 323 European data: increasing the mean natural carriage duration, transmission rate, and 324 treatment rate to match observed data, and ignoring mixing with any other countries (f 325 = 1), while keeping other parameters the same. We find that a comparatively greater 326 vaccine efficacy is needed to reduce the prevalence of resistant carriage in a high-327 burden, high-resistance setting (Fig. 5). This is particularly true under the "Growth 328 competition" model, because in this model resistant carriage only declines as total 329 pneumococcal carriage declines, and it is particularly difficult to reduce overall carriage 330 in a high-transmission setting. Simultaneously, vaccination may have a comparatively 331 greater impact in high-burden settings because of a comparatively higher incidence of 332 disease: for example, Kenya is estimated to have an 8.8-fold higher incidence of severe 333 pneumococcal pneumonia than the average in Europe (58).

334

335 Accounting for additional between-country variation does not substantially alter

336 predictions. Our focus thus far has been on the impact of the four identified 337 mechanisms *per se* upon resistance evolution, and accordingly we have focused on 338 reproducing the positive association between treatment rate and resistance frequency 339 rather than attempting to capture the additional variability in resistance frequency 340 between countries not accounted for by the reported treatment rate alone (Fig. 2a). This additional variability may partially stem from differences in national testing and 341 342 reporting practices, or between-country differences in the distribution of pneumococcal 343 serotypes among invasive isolates (59). However, another possibility is that this 344 additional variability in resistance results from systematic differences in pathogen 345 biology or host behaviour across countries which can be captured by our modelling 346 framework.

348 To help identify which model parameters could account for this variability, we relax the 349 assumption that only the treatment rate varies across countries, and perform Bayesian 350 maximum *a posteriori* fitting, assuming one additional parameter (*c*, *b*, β , *u*, *f*, *z*, *g*, κ , *a*, δ , 351 or k) is free to vary between countries while other parameters are held constant. We 352 find that additional variation in resistance between countries can be explained by 353 variation in certain other parameters, depending upon which model is used (Fig. 6a–b). 354 Importantly, among those parameters for which additional variation between countries 355 can explain the variation in resistance (Fig. 6c), predictions for the overall impact of 356 vaccination remain similar with the major differences still attributable to the underlying 357 mechanism of resistance evolution (Fig. 6d; Supplementary Figs. 3–14). Models that 358 could make more accurate country-specific predictions would need to account for the 359 effects of demographic structure, differences in carriage prevalence and disease rates 360 between settings, and variable vaccine protection among individuals.

- 361
- 362

363

Discussion

364 We have identified four mechanisms of resistance evolution that are capable of 365 recapitulating the observed relationship between penicillin consumption and penicillin 366 non-susceptibility in *S. pneumoniae* across Europe. These mechanisms are not mutually 367 exclusive, but the relative importance of each is predicted to have a substantial impact 368 upon predictions for resistance evolution under vaccination. In particular, the 369 "directionality" of within-host competition—that is, whether, on average, within-host 370 competition tends to benefit resistant or sensitive strains—strongly determines 371 whether vaccination selects for a decrease or an increase in antibiotic resistance in the 372 long term. This directionality may vary between pathogens, but is also sensitive to the 373 antibiotic treatment rate, and so may also vary between settings. Although we have 374 focused on competition between sensitive and resistant strains of *S. pneumoniae* only, 375 competition between serotypes (24) and with other bacteria colonizing the 376 nasopharynx will also impact upon resistance evolution, and determining the 377 importance of these other sources of within-host competition is crucial. 378 379 A key result of our models is that the mode of vaccine protection—whether acquisition-

377 A key result of our models is that the mode of vaccine protection—whether acquisition
 380 blocking or clearance-accelerating—has an appreciable impact upon resistance

381 evolution. Whole-cell and purified-protein pneumococcal vaccines may induce antibody-mediated humoral immunity, CD4+ T helper-17 cell-mediated immunity, or 382 both, with the type of immunity mediating pneumococcal acquisition, carriage, and 383 384 disease in ways that are still not fully understood (49–51). By modelling both modes of 385 vaccine action, we have highlighted that clearance-accelerating vaccines have increased 386 potential for preventing the spread of resistance, because in shortening the duration of 387 asymptomatic carriage they limit the fitness advantage of resistant pathogens under 388 selection pressure from antibiotic use.

389

390 The prevalence of penicillin non-susceptibility in *S. pneumoniae* has remained largely 391 stable in Europe between 2005–2017, a period which saw the incorporation of PCV into 392 the routine immunization schedules of most European countries (60). However, 393 because serotype replacement has largely negated any vaccine impact on the 394 prevalence of nasopharyngeal pneumococcal carriage (10, 11), it is not clear that we 395 should expect to see any effects of competition-mediated resistance evolution following 396 a serotype-specific vaccine such as PCV—particularly given the complexity of detecting 397 vaccine-attributable changes in resistance in a population-level associational study that 398 would be confounded both by serotype replacement and by other changes in resistance 399 evolution that might be expected to occur at a national level over the course of multiple 400 years.

401

402 Under the "Treatment diversity" and "Pathogen diversity" models, we have argued that 403 universal pneumococcal vaccination will have little impact upon the long-term 404 evolution of antibiotic resistance because it does not change the sources of diversity 405 that modulate resistance evolution. Nonetheless, it is possible to target vaccines such 406 that this diversity is harnessed to manage resistance: high-resistance serotypes could 407 be targeted with a serotype-specific vaccine, or high-treatment subpopulations could be 408 targeted for vaccination in order to more effectively manage resistance. Indeed, 409 vaccination does have an additional inhibiting effect upon resistance in our models because of the latter effect. This inhibition occurs because the vaccine has a relatively 410 411 greater impact upon transmission in populations where the prevalence of carriage is 412 already low, which in our models occur in countries or subpopulations with more 413 antibiotic consumption. Since these populations drive resistance more strongly, the

414 vaccine's comparatively greater impact in these populations tends to moderately inhibit 415 resistance overall. We note that while previous work (38) has suggested that resistance evolution under a "Pathogen diversity" model results in a "stepped" resistance pattern 416 417 in which D-types are either fully sensitive or fully resistant at equilibrium, we find that 418 small amounts of mixing between populations can smooth out this pattern and allow 419 intermediate rates of resistance within subtypes (Supplementary Fig. 2). Finally, while 420 we have framed "Treatment competition" and "Growth competition" as two distinct 421 alternatives, they can instead be viewed as endpoints on a continuum, with possible 422 models of resistance evolution for which both c > 0 and b > 0 lying between them. The impact of vaccination on resistance in such a model would depend upon the relative 423 424 importance of treatment-mediated and growth-mediated competition.

425

426 This analysis has necessarily made simplifying assumptions. We have focused on 427 prevalence (the fraction of individuals who are carriers) rather than incidence (the rate 428 of new carriage episodes) of nasopharyngeal carriage in presenting our findings. There 429 is evidence that pneumococcal disease progression is more likely to occur shortly after 430 nasopharyngeal acquisition (61), suggesting that incidence may be more relevant than 431 prevalence for predicting disease outcomes. Of particular note, recent modelling work 432 has suggested that clearance-accelerating vaccines can increase rates of pneumococcal 433 acquisition, if extended carriage is protective against new acquisition (62). However, it 434 is not obvious how to compare rates of carriage acquisition across the models examined 435 in this paper, particularly because co-colonisation is explicitly tracked—and fitted to 436 data—in some but not all models. More work is required to clarify the links between 437 acquisition, carriage, and disease across competing models of pneumococcal 438 transmission. Additionally, we have assumed that antibiotic treatment rates among 439 pneumococcal carriers remains constant after the introduction of a vaccine, even 440 though treatment rates dropped in many settings following PCV introduction (5, 9). 441 However, for a universal pneumococcal vaccine that reduces antibiotic treatment rates 442 because it reduces carriage and thereby prevents antibiotic-treatable disease, any 443 reduction in treatment will only occur among individuals who, because of vaccine 444 protection, are not pneumococcal carriers, all else being equal. It might then be 445 expected that treatment rates in carriers would remain equally high among those individuals for whom vaccine protection has failed. 446

447

448 Our work helps resolve the question: What explains the persistent coexistence between resistant and sensitive strains of *S. pneumoniae*? (25) by demonstrating that multiple 449 450 mechanisms are capable of explaining trends of resistance across European countries. 451 Since there is empirical support for within-host competition between sensitive and 452 resistant pathogen strains (63–66), heritable differences in the propensity for resistance 453 within species (38), and within-country heterogeneity in antibiotic consumption rates 454 (67–69), all of these mechanisms likely contribute to this pattern. Our results 455 contextualize previous mathematical studies which have variously suggested that 456 serotype-specific vaccination may increase (24), decrease (22) or have no impact upon 457 (18) the frequency of resistance in *S. pneumoniae*. While the potential for vaccination to 458 promote resistance because of competition between sensitive and resistant strains has 459 been described previously (24), we have shown that vaccination can either promote or 460 inhibit resistance depending upon the directionality of within-host competition. While 461 vaccines targeting highly-resistant serotypes can decrease resistance (22), we have 462 shown that a serotype-independent vaccine promoting accelerated natural clearance 463 can decrease resistance across all circulating subtypes. And where single-population 464 models have found no long-term impact of vaccination on resistance frequency (18), we 465 have shown that in multi-population models, vaccination can inhibit resistance if it has 466 a larger impact in subpopulations that consume more antibiotics. The direction and 467 magnitude of this effect would depend upon variation in vaccine uptake, vaccine 468 efficacy, and pathogen transmission among subpopulations, and we have not 469 systematically explored this variation here.

470

A highly efficacious serotype-independent pneumococcal vaccine can indeed reduce the
overall burden of antibiotic-resistant pneumococcal infections. However, the long-term
effect upon resistance of a vaccine with intermediate efficacy is less certain, as vaccine
impact depends crucially upon the mechanisms that drive resistance evolution. Thus,
empirical investigation of pathogen competitive dynamics—and the impact of settingspecific factors on these dynamics—is needed to make accurate predictions of vaccine
impact on resistant infections.

478

479

Methods

480

481 *Study design.* This study comprises four parts: a literature search used to identify 482 plausible mechanisms through which coexistence can be maintained between sensitive 483 and resistant pneumococcal strains across a range of antibiotic treatment rates; a 484 mathematical modelling study embedding these mechanisms of resistance evolution in 485 four models of pneumococcal transmission; a Bayesian statistical analysis to fit these 486 models to empirically observed frequencies of penicillin non-susceptibility and 487 community penicillin consumption across 27 European countries for the year 2007; and 488 a vaccine impact analysis using these fitted models to forecast the impact of a universal 489 pneumococcal vaccine. We use data from 2007 because changes in pneumococcal 490 resistance reporting standards for some countries after this year hamper the between-491 country comparability of data (70). Our objectives were to identify the mechanisms 492 potentially responsible for maintaining coexistence between resistant and sensitive 493 pneumococci in Europe, and to determine whether the impact of vaccination on the 494 evolution of resistance depends upon which mechanism is assumed to operate. 495

496 *Mechanisms driving resistance.* We searched PubMed using the terms: (AMR OR ABR OR 497 ((antimicrobial OR antibiotic) AND resist*)) AND ((model OR modelling OR modeling) 498 AND (dynamic* OR transmi* OR mathematical)) AND (coexist* OR intermediate). This 499 yielded 93 papers (Supplementary Table 1). We included all papers containing a 500 dynamic host-to-host pathogen transmission model analysing both sensitive and 501 resistant strains with stable coexistence as an outcome of the model. From the 11 502 studies meeting these criteria, we identified nine unique mechanisms, two of which 503 correspond to alternative parameterisations of a within-host competition model. We 504 ruled out four mechanisms because of implausibility or because previous work shows 505 that the mechanism does not bring about substantial coexistence, leaving four 506 mechanisms (Table 1).

507

508 *Model framework.* We analyse the evolution of antibiotic resistance by tracking the 509 transmission of resistant and sensitive bacterial strains among hosts in a set of *M* 510 countries indexed by $m \in \{1, 2, ..., M\}$ using systems of ordinary differential equations. 511

512 In a simple model, hosts can either be non-carriers (X), carriers of the sensitive strain

513 (S), or carriers of the resistant strain (R). Omitting country-specific subscripts *m* for

514 concision, model dynamics within a country are captured by

515

516 $dS/dt = \lambda_{S}X - (u + \tau)S$ 517 $dR/dt = (1 - c)\lambda_{R}X - uR$ 518 X = 1 - S - R, (1)

519

520 where λ_s is the force of infection of the sensitive strain, λ_R is the force of infection of the 521 resistant strain, *c* is the transmission cost of resistance, *u* is the rate of natural 522 clearance, and τ is the treatment rate. In this model, in a given country, the total 523 carriage of the sensitive strain is *S* and the total carriage of the resistant strain is *R*.

524 Force of infection terms are defined below.

525

526 The "Treatment diversity" model extends the simple model (eq. 1) by structuring each 527 country into multiple subpopulations that exhibit different rates of antibiotic treatment 528 and make contact with each other at unequal rates (25, 34, 35, 71). In each country, we 529 model *N* equally-sized representative subpopulations indexed by $i \in \{1, 2, ..., N\}$, where 530 we assume N = 10. Dynamics within a country are

531

532	$\mathrm{d}S_i/\mathrm{d}t = \lambda_{\mathrm{S},i}X - (u + \tau_i)S$	
533	$\mathrm{d}R_i/\mathrm{d}t = (1-c)\lambda_{\mathrm{R},i}X - uR$	
534	$X_i = 1 - S_i - R_i$	(2)

535

where we assume that treatment rates of subpopulations within a country approximately follow a gamma distribution with shape parameter κ and mean treatment rate τ . Accordingly, the rate of antibiotic consumption in subpopulation *i* is $\tau_i = \int_{Q_{\Gamma}(\frac{i-1}{N}|\kappa)}^{Q_{\Gamma}(\frac{i}{N}|\kappa)} t P_{\Gamma}(t|\kappa) dt$, where $Q_{\Gamma}(q|\kappa)$ is the quantile *q* of the gamma distribution with shape κ and $P_{\Gamma}(t|\kappa)$ is the probability density at *t* of the same gamma distribution. The "Pathogen diversity" model extends the simple model (eq. 1) by structuring the

543 pathogen population into *D* different "D-types" (we assume D = 25), each with a

different natural clearance rate, where each type is kept circulating by diversifying
selection acting on D-type (*38*). Dynamics within a country are

546
547
$$dS_d/dt = q_d \lambda_{S,d} X - (u_d + \tau) S_d$$
548
$$dR_d/dt = q_d (1 - c) \lambda_{R,d} X - u_d R_d$$
549
$$X = 1 - \Sigma_d (S_d + R_d)$$
550 (3)

550

551 where $q_d = (1 - \frac{S_d + R_d}{\sum_{j=1}^D (S_j + R_j)} + \frac{1}{D})^a$ is the strength of diversifying selection for D-type $d \in$ 552 $\{1, 2, ..., D\}$ and $u_d = u \left(1 + \delta \left(2\frac{d-1}{D-1} - 1\right)\right)$ is the clearance rate for D-type d, where

model parameter *a* is the power of diversifying selection and model parameter δ is the

range of clearance rates (*38*). In a given country, the total carriage of the type-*d*

sensitive strain is S_d and the total carriage of the type-*d* resistant strain is R_d .

556

Finally, the within-host competition models (26) allow hosts to carry a mix of both
strains. Hosts can carry the sensitive strain with a small complement of the resistant
strain (S_R) or the resistant strain with a small complement of the sensitive strain (R_s).
Dynamics within a country are

561

562	$dS/dt = \lambda_S X - (u + \tau)S - k(1 - c)\lambda_R S + b_0 S_R$	
563	$\mathrm{d}S_R/\mathrm{d}t = k(1-c)\lambda_R S - (u+\tau)S_R + bR_S - b_0S_R$	
564	$dR_S/dt = k\lambda_S R - (u + \tau)R_S - bR_S$	
565	$dR/dt = (1 - c)\lambda_R X - uR - k\lambda_S R + \tau(S_R + R_S)$	
566	$X=1-S-R-S_R-R_S,$	(4)

567

568 where *k* is the rate of co-colonisation relative to primary colonisation, *b* is the withinhost growth benefit of sensitivity (i.e. the rate of the $R_S \rightarrow S_R$ transition), and $b_0 = 4b$ is 569 570 the rate of the $S_R \rightarrow S$ transition as a function of this growth benefit. In a given country, 571 the total carriage of the sensitive strain is $S + S_R$ and the total carriage of the resistant strain is $R + R_s$. "Treatment competition" assumes the cost of resistance is incurred by 572 reduced transmission potential (b = 0 and c > 0), while "Growth competition" assumes 573 574 that the cost of resistance is incurred through decreased within-host growth (b > 0 and 575 c = 0).

576

In equations 1, 3 and 4, the force of infection of a particular strain A in country m is $\lambda_A =$ 577 $\beta(fA_{\text{tot}|m} + (1-f)\sum_{\ell=1}^{M} h_{\ell}A_{\text{tot}|\ell})$, where β is the transmission rate, *f* is the between-578 579 country assortativity, h_{ℓ} is the relative population size of country *m* (such that $\sum_{\ell} h_{\ell} =$ 1), and $A_{tot|\ell}$ is the total carriage of strain A in country ℓ . The probability with which 580 581 individuals contact an individual from another country, 1 - f, captures those contacts 582 made with individuals from another country in either one's home country or a foreign 583 country. In equation 2, the force of infection of a particular strain A in subpopulation i of country *m* is $\lambda_{A,i} = \beta \left(f \left(g A_{tot|m,i} + (1-g) \sum_{j=1}^{N} \frac{1}{N} A_{tot|m,j} \right) + (1-g) \sum_{j=1}^{N} \frac{1}{N} A_{tot|m,j} \right)$ 584 $f \sum_{\ell=1}^{M} \sum_{j=1}^{N} \frac{h_{\ell}}{N} A_{tot|\ell,j}$, where g is the within-country assortativity and $A_{tot|\ell,j}$ is the 585 total carriage of strain A in subpopulation *j* of country ℓ . 586 587

588 Data and model fitting. We extracted community penicillin consumption and penicillin non-susceptibility in *S. pneumoniae* invasive isolates from databases made available by 589 590 the ECDC (13, 28). We assume that community penicillin consumption drives penicillin 591 resistance, that antibiotic consumption is independent of whether an individual is 592 colonised by pneumococcus, and that resistance among invasive bacterial isolates is 593 representative of resistance among circulating strains more broadly. Countries report 594 community penicillin consumption in defined daily doses (DDD) per thousand 595 individuals per day. To transform this bulk consumption rate into the rate at which 596 individuals undertake a course of antibiotic therapy, we analysed prescribing data from 597 eight European countries, estimating that, on average, 5 DDD in the population at large 598 correspond to one treatment course for a child under 5 years of age. This conversion 599 rate varies between countries (Supplementary Table 4), but since the data are incomplete (8 of 27 countries) we have not explicitly accounted for this variability in 600 601 our main model fitting results.

602

Our model framework tracks carriage of *S. pneumoniae* among children aged 0–5 years,
the age group driving both transmission and disease. In European countries, we assume
that the prevalence of pneumococcal carriage in under-5s is 50% (*11, 42*) and the
average duration of carriage is 47 days (*47, 48*). We calculate the average incidence of *S. pneumoniae*-caused severe pneumonia requiring hospitalisation as 610 per million

children under 5 per year (*58*) across the European countries in our data set. See
Supplementary Tables 3, 5, and 6 for details of calculations relating to pneumococcal

- 610 carriage duration and disease incidence.
- 611
- 612 We use Bayesian inference via differential evolution Markov chain Monte Carlo (72) to
- 613 identify model parameters that are consistent with empirical data. Country *m* has
- 614 antibiotic treatment rate τ_m and reports r_m of n_m isolates are resistant. Over all M
- 615 countries, these data are denoted $\tau = (\tau_1, \tau_2, ..., \tau_M)$, $r = (r_1, r_2, ..., r_M)$, and n =
- 616 $(n_1, n_2, ..., n_M)$, respectively. The probability of a given set of model parameters θ is
- 617 then
- 618 $P(\theta|\tau, r, n) \propto P(\tau, r, n|\theta)P(\theta),$
- 619

620 where $P(\theta)$ is the prior probability of parameters θ and

621
$$P(\tau, r, n|\theta) = C(Y = Y(\tau|\theta)) \prod_{m=1}^{M} R(r = r_m, n = n_m, \rho = \rho(\tau_m|\theta))^{N_m/\overline{N}}$$

622

is the likelihood of data τ , r, n given model parameters θ . Above, $Y(\theta)$ is the average 623 624 model-predicted prevalence of carriage across all countries and $\rho(\tau_m | \theta)$ is the model-625 predicted resistance prevalence for country *m*. *C*(*Y*) is the credibility of prevalence of 626 carriage Y and $R(r,n,\rho)$ is the credibility of r out of n isolates being resistant when the 627 model-predicted resistance prevalence is ρ . For C(Y), we use a normal distribution with mean 0.5 and standard deviation 0.002. For $R(r,n,\rho)$, we use $R(r,n,\rho) =$ 628 $\int_0^1 T(x|\mu = \rho, \sigma = \sigma(\theta)) {n \choose r} x^r (1-x)^{n-r} dx$, a binomial distribution where the 629 probability of success is modelled as a [0,1]-truncated normal distribution centred on ρ 630 631 and with standard deviation σ . The parameter σ captures the unexplained betweencountry variation in resistance frequency. Here, $T(x|\mu, \sigma) = \frac{\varphi(x|\mu, \sigma)}{(\Phi(1|\mu, \sigma) - \Phi(0|\mu, \sigma))}$, where 632 $\varphi(\mu,\sigma) = \frac{1}{\sqrt{2\pi\sigma^2}} exp\left(-\frac{(x-\mu)^2}{2\sigma^2}\right)$ is the untruncated normal PDF and $\varphi(\mu,\sigma) = \frac{1}{2}(1+\omega)$ 633 $erf\left(\frac{x-\mu}{\sigma\sqrt{2}}\right)$) is the untruncated normal cumulative distribution function. Finally, N_m is the 634 population size of country *m* and \overline{N} is the average population size across all countries; 635 the exponent N_m/\overline{N} allows us to weight the importance of each country by its 636

bioRxiv preprint doi: https://doi.org/10.1101/610188; this version posted October 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

637 population size, which allows a closer fit with the overall resistance prevalence across 638 all countries.

639

640 We adopt $c \sim \text{Beta}(\alpha = 1.5, \beta = 8.5), b \sim \text{Gamma}(\kappa = 2, \theta = 0.5), \beta \sim \text{Gamma}(\kappa = 1.5, \beta = 1.5), \beta \sim 1.5), \beta \sim 1.5, \beta \sim 1.5,$ 5, $\theta = 0.35$), $g \sim \text{Beta}(\alpha = 10, \beta = 1.5)$, $\kappa \sim \text{Gamma}(\kappa = 4, \theta = 2)$, $\alpha \sim \text{Gamma}(\kappa = 10, \beta = 1.5)$ 641 2, $\theta = 5$), $\delta \sim \text{Beta}(\alpha = 20, \beta = 25)$, and $k \sim \text{Normal}(\mu = 1, \sigma = 0.5)$ as weakly 642 643 informative prior distributions for model fitting. We set the unexplained between-644 country variation in resistance prevalence σ to 0.06 across all models based on a 645 preliminary round of model fitting with σ as a free parameter, and set the between-646 country assortativity f to 0.985 (*i.e.*, 1.5% of contacts occur with individuals from a 647 different country) based on rates of travel within the EU. See Supplementary Table 7 for 648 MCMC diagnostics. 649 650 To match model predictions to a high-burden setting, we increase the duration of 651 carriage to 71.4 days; increase the transmission rate by a factor of 3.49 (Treatment 652 diversity), 3.62 (Pathogen diversity), 3.61 (Treatment competition), or 3.20 (Growth 653 competition), so that carriage prevalence reaches 90.0%; and increase the antibiotic 654 consumption rate to 1.670, 1.458, 1.138, or 5.887 courses per person per year, 655 respectively, so that resistance prevalence reaches 81.4%. 656 657 Interventions. Interventions have the following impact on model parameters: for the acquisition-blocking vaccine, the transmission rate becomes $\beta' = (1 - \varepsilon_a) \beta$; for the 658 659 clearance-accelerating vaccine, the clearance rate becomes $u' = u/(1-\varepsilon_c)$; and under

660 antibiotic stewardship, the average treatment rate in each country *m* becomes $\tau_m' = \tau_m$ 661 $(1-\varepsilon_s)$.

662

663 *Capturing additional between-country variation in resistance frequency.* We begin by 664 finding the maximum *a posteriori* model fits according to the likelihood and prior 665 distributions for each of the four models of resistance evolution. This identifies the following parameter values for each model. "Treatment diversity": $\beta = 1.41$, c = 0.124, g666 667 = 0.976, and κ = 2.22. "Pathogen diversity": β = 1.33, *c* = 0.191, *a* = 10.8, and δ = 0.608. "Treatment competition": $\beta = 1.42$, c = 0.191, and k = 1.64. "Growth competition": $\beta = 0.191$ 668 669 1.39, *b* = 0.195, and *k* = 1.61. Then, we perform maximum *a posteriori* model fits for each

670 potentially-varying parameter under each model, allowing the varying parameter to take on a different value for each country and fixing other parameters at their maximum 671 a posteriori values as determined in the previous step, or at specific assumed values for 672 673 u = 0.65, f = 0.985, and z = 5. For the second step, we use a modified likelihood function 674

675
$$P(\tau, r, n|\theta) = C(Y = Y(\tau|\theta)) \prod_{m=1}^{M} \phi\left(\mu = \frac{r_m + 1}{n_m + 2}, \sigma = 0.001 \middle| x = \rho(\tau_m|\theta)\right)^{N_m/\overline{N}},$$

676

where $\phi(\mu, \sigma | x)$ is the normal probability density function. This modified likelihood 677 678 function ensures that the model-predicted resistance frequency for each country is matched as closely as possible to the maximum-likelihood resistance prevalence $\frac{r_m+1}{n_m+2}$ 679 680 (*i.e.*, assuming a uniform prior on resistance frequency) for each country *m*, so that 681 model fits are comparable across different varying parameters. We use the Nelder-Mead 682 algorithm to maximize the posterior probability in both steps.

683

684 Supplementary Figs. 3–6 show maximum *a posteriori* fits when allowing an additional 685 parameter to vary freely between countries, along with the parameter values identified by model fitting. Supplementary Figs. 7–10 show the impact of vaccination, focusing on 686 687 those parameters for which model fitting was able to capture the observed variability in resistance frequency between countries (*i.e.*, those parameters plotted to the left of the 688 689 dashed line in Fig. 6b of the main text). Supplementary Figs. 11–14 show the impact of 690 vaccination for the remaining parameters.

bioRxiv preprint doi: https://doi.org/10.1101/610188; this version posted October 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

691	List of Supplementary Materials
692	
693	Supplementary Table 1. Literature review.
694	Supplementary Table 2. Summary of model parameters.
695	Supplementary Table 3. Carriage duration.
696	Supplementary Table 4. Penicillin consumption.
697	Supplementary Table 5. Pneumococcal morbidity.
698	Supplementary Table 6. Carriage duration (Kilifi).
699	Supplementary Table 7. MCMC diagnostics.
700	Supplementary Fig. 1. Patterns of penicillin non-susceptibility across European
701	countries, 2005–2017.
702	Supplementary Fig. 2. Carriage and resistance of D-types in "Pathogen variability"
703	model.
704	Supplementary Fig. 3. Varying-parameter fits for "Treatment diversity" model.
705	Supplementary Fig. 4. Varying-parameter fits for "Pathogen diversity" model.
706	Supplementary Fig. 5. Varying-parameter fits for "Treatment competition" model.
707	Supplementary Fig. 6. Varying-parameter fits for "Growth competition" model.
708	Supplementary Fig. 7. Vaccine impact for "Treatment diversity" model, varying
709	parameters <i>c</i> and <i>z</i> .
710	Supplementary Fig. 8. Vaccine impact for "Pathogen diversity" model, varying
711	parameters c , δ , and z .
712	Supplementary Fig. 9. Vaccine impact for "Treatment competition" model, varying
713	parameters β, <i>c</i> , <i>u</i> , <i>k</i> , and <i>z</i> .
714	Supplementary Fig. 10. Vaccine impact for "Growth competition" model, varying
715	parameters <i>b</i> and <i>z</i> .
716	Supplementary Fig. 11. Vaccine impact for "Treatment diversity" model, varying other
717	parameters.
718	Supplementary Fig. 12. Vaccine impact for "Pathogen diversity" model, varying other
719	parameters.
720	Supplementary Fig. 13. Vaccine impact for "Treatment competition" model, varying
721	other parameters.
722	Supplementary Fig. 14. Vaccine impact for "Growth competition" model, varying other
723	parameters.

724		References	
725			
726	1.	J. O'Neill, "Vaccines and alternative approaches: reducing our dependence on	
727		antimicrobials" (2016), (available at http://amr-	
728		review.org/sites/default/files/Vaccines and alternatives_v4_LR.pdf).	
729	2.	M. Lipsitch, R. Siber, How Can Vaccines Contribute to Solving the Antimicrobial	
730		Resistance Problem ? 7, 1–8 (2016).	
731	3.	K. E. Atkins, M. Lipsitch, Can antibiotic resistance be reduced by vaccinating	
732		against respiratory disease? Lancet Respir. Med. 6, 820–821 (2018).	
733	4.	J. P. Sevilla, D. E. Bloom, D. Cadarette, M. Jit, M. Lipsitch, Toward economic	
734		evaluation of the value of vaccines and other health technologies in addressing	
735		AMR. Proc. Natl. Acad. Sci. 115, 12911–12919 (2018).	
736	5.	K. P. Klugman, S. Black, Impact of existing vaccines in reducing antibiotic	
737		resistance: Primary and secondary effects. Proc. Natl. Acad. Sci. 115, 12896–	
738		12901 (2018).	
739	6.	M. H. Kyaw, R. Lynfield, W. Schaffner, A. S. Craig, J. Hadler, A. Reingold, A. R.	
740		Thomas, L. H. Harrison, N. M. Bennett, M. M. Farley, R. R. Facklam, J. H. Jorgensen,	
741		J. Besser, E. R. Zell, A. Schuchat, C. G. Whitney, Effect of Introduction of the	
742		Pneumococcal Conjugate Vaccine on Drug-Resistant Streptococcus pneumoniae.	
743		N. Engl. J. Med. 354 , 1455–1463 (2006).	
744	7.	D. Thorrington, N. Andrews, J. Stowe, E. Miller, A. J. van Hoek, Elucidating the	
745		impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis	
746		and otitis media hospital admissions in England using a composite control. BMC	
747		<i>Med.</i> 16 , 1–14 (2018).	
748	8.	C. Chen, F. Cervero Liceras, S. Flasche, S. Sidharta, J. Yoong, N. Sundaram, M. Jit,	
749		Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global	
750		modelling analysis. <i>Lancet Glob. Heal.</i> 7 , e58–e67 (2019).	
751	9.	K. J. Wilby, D. Werry, A review of the effect of immunization programs on	
752		antimicrobial utilization. Vaccine. 30 , 6509–6514 (2012).	
753	10.	W. P. Hanage, J. A. Finkelstein, S. S. Huang, S. I. Pelton, A. E. Stevenson, K.	
754		Kleinman, V. L. Hinrichsen, C. Fraser, Evidence that pneumococcal serotype	
755		replacement in Massachusetts following conjugate vaccination is now complete.	
756		<i>Epidemics.</i> 2 , 80–84 (2010).	

757	11.	S. Flasche, A. J. Van Hoek, E. Sheasby, P. Waight, N. Andrews, C. Sheppard, R.
758		George, E. Miller, Effect of pneumococcal conjugate vaccination on serotype-
759		specific carriage and invasive disease in England: a cross-sectional study. <i>PLoS</i>
760		<i>Med.</i> 8 , e1001017 (2011).
761	12.	J. A. Lewnard, W. P. Hanage, Making sense of differences in pneumococcal
762		serotype replacement. <i>Lancet Infect. Dis.</i> 3099 (2019), doi:10.1016/s1473-
763		3099(18)30660-1.
764	13.	European Centre for Disease Prevention and Control, Antimicrobial consumption
765		rates by country (2018), (available at
766		http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/esac-net-
767		database/Pages/Antimicrobial-consumption-rates-by-country.aspx).
768	14.	World Health Organization, WHO vaccine pipeline tracker (2019), (available at
769		https://www.who.int/immunization/research/vaccine_pipeline_tracker_spreads
770		heet/en/).
771	15.	G. L. Masala, M. Lipsitch, C. Bottomley, S. Flasche, Exploring the role of
772		competition induced by non-vaccine serotypes for herd protection following
773		pneumococcal vaccination. J. R. Soc. Interface. 14 (2017),
774		doi:10.1098/rsif.2017.0620.
775	16.	K. E. Atkins, E. I. Lafferty, S. R. Deeny, N. G. Davies, J. V. Robotham, M. Jit, Use of
776		mathematical modelling to assess the impact of vaccines on antibiotic resistance.
777		Lancet Infect. Dis. 18, e204–e213 (2018).
778	17.	K. E. Atkins, S. Flasche, Vaccination to reduce antimicrobial resistance. Lancet
779		<i>Glob. Heal.</i> 6 , e252 (2018).
780	18.	L. Temime, D. Guillemot, P. Y. Boëlle, Short- and long-term effects of
781		pneumococcal conjugate vaccination of children on penicillin resistance.
782		Antimicrob. Agents Chemother. 48 , 2206–2213 (2004).
783	19.	L. Temime, P. Y. Boëlle, A. J. Valleron, D. Guillemot, Penicillin-resistant
784		pneumococcal meningitis: High antibiotic exposure impedes new vaccine
785		protection. <i>Epidemiol. Infect.</i> 133 , 493–501 (2005).
786	20.	L. Opatowski, L. Temime, E. Varon, R. Leclerc, H. Drugeon, PY. Boëlle, D.
787		Guillemot, Antibiotic Innovation May Contribute to Slowing the Dissemination of
788		Multiresistant Streptococcus pneumoniae: The Example of Ketolides. <i>PLoS One</i> . 3 ,
789		e2089 (2008).

790	21.	T. Van Effelterre, M. R. Moore, F. Fierens, C. G. Whitney, L. White, S. I. Pelton, W. P.
791		Hausdorff, A dynamic model of pneumococcal infection in the United States:
792		Implications for prevention through vaccination. Vaccine. 28, 3650–3660 (2010).
793	22.	M. D. De Cellès, M. Pons-Salort, E. Varon, M. A. Vibet, C. Ligier, V. Letort, L.
794		Opatowski, D. Guillemot, Interaction of vaccination and reduction of antibiotic use
795		drives unexpected increase of pneumococcal meningitis. <i>Sci. Rep.</i> 5 , 1–11 (2015).
796	23.	P. K. Mitchell, M. Lipsitch, W. P. Hanage, Carriage burden, multiple colonization
797		and antibiotic pressure promote emergence of resistant vaccine escape
798		pneumococci. <i>Philos. Trans. R. Soc. B Biol. Sci.</i> 370 , 3–9 (2015).
799	24.	U. Obolski, J. Lourenço, C. Thompson, R. Thompson, A. Gori, S. Gupta, Vaccination
800		can drive an increase in frequencies of antibiotic resistance among nonvaccine
801		serotypes of Streptococcus pneumoniae. Proc. Natl. Acad. Sci. 115, 3102–3107
802		(2018).
803	25.	C. Colijn, T. Cohen, C. Fraser, W. Hanage, E. Goldstein, N. Givon-Lavi, R. Dagan, M.
804		Lipsitch, What is the mechanism for persistent coexistence of drug-susceptible
805		and drug-resistant strains of Streptococcus pneumoniae? J. R. Soc. Interface. 7,
806		905–919 (2010).
807	26.	N. G. Davies, S. Flasche, M. Jit, K. E. Atkins, Within-host dynamics shape antibiotic
808		resistance in commensal bacteria. <i>Nat. Ecol. Evol.</i> (2019), doi:10.1038/s41559-
809		018-0786-x.
810	27.	H. Goossens, M. Ferech, R. Vander Stichele, M. Elseviers, Outpatient antibiotic use
811		in Europe and association with resistance: A cross-national database study.
812		Lancet. 365 , 579–587 (2005).
813	28.	European Centre for Disease Prevention and Control, Data from the ECDC
814		Surveillance Atlas - Antimicrobial resistance (2016), (available at
815		https://ecdc.europa.eu/en/antimicrobial-resistance/surveillance-and-disease-
816		data/data-ecdc).
817	29.	M. Lipsitch, C. Colijn, T. Cohen, W. P. Hanage, C. Fraser, No coexistence for free:
818		Neutral null models for multistrain pathogens. <i>Epidemics</i> . 1 , 2–13 (2009).
819	30.	P. Rodrigues, M. G. M. Gomes, C. Rebelo, Drug resistance in tuberculosis-a
820		reinfection model. <i>Theor. Popul. Biol.</i> 71 , 196–212 (2007).
821	31.	O. Patterson-Lomba, B. M. Althouse, G. M. Goerg, L. Hébert-Dufresne, Optimizing
822		Treatment Regimes to Hinder Antiviral Resistance in Influenza across Time

823		Scales. <i>PLoS One</i> . 8 , 1–11 (2013).
824	32.	I. M. Hastings, Complex dynamics and stability of resistance to antimalarial drugs.
825		Parasitology. 132 , 615–624 (2006).
826	33.	R. Sergeev, C. Colijn, T. Cohen, Models to understand the population-level impact
827		of mixed strain M. tuberculosis infections. J. Theor. Biol. 280, 88–100 (2011).
828	34.	F. Blanquart, S. Lehtinen, M. Lipsitch, C. Fraser, The evolution of antibiotic
829		resistance in a structured host population. J. R. Soc. Interface. 15 (2018),
830		doi:10.1098/rsif.2018.0040.
831	35.	M. S. Krieger, A. L. Hill, Long-term coexistence and regional heterogeneity of
832		antibiotic-resistant infections reproduced by a simple spatial model. <i>bioRxiv</i> . 14 ,
833		469171 (2018).
834	36.	R. Kouyos, E. Klein, B. Grenfell, Hospital-Community Interactions Foster
835		Coexistence between Methicillin-Resistant Strains of Staphylococcus aureus. PLoS
836		Pathog. 9 (2013), doi:10.1371/journal.ppat.1003134.
837	37.	M. F. Boni, M. W. Feldman, Evolution of Antibiotic Resistance By Human and
838		Bacterial Niche Construction. Evolution (N. Y). 59, 477 (2006).
839	38.	S. Lehtinen, F. Blanquart, N. J. Croucher, P. Turner, M. Lipsitch, C. Fraser, Evolution
840		of antibiotic resistance is linked to any genetic mechanism affecting bacterial
841		duration of carriage. Proc. Natl. Acad. Sci. 114 , 1075–1080 (2017).
842	39.	D. J. Austin, K. G. Kristinsson, R. M. Anderson, The relationship between the
843		volume of antimicrobial consumption in human communities and the frequency
844		of resistance. <i>Proc. Natl. Acad. Sci.</i> 96 , 1152–1156 (1999).
845	40.	A. B. Beams, D. J. A. Toth, K. Khader, F. R. Adler, Harnessing intra-host strain
846		competition to limit antibiotic resistance: mathematical model results. Bull. Math.
847		<i>Biol.</i> 78 , 1828–1846 (2016).
848	41.	K. Græsbøll, S. S. Nielsen, N. Toft, L. E. Christiansen, How fitness reduced,
849		antimicrobial resistant bacteria survive and spread: A multiple pig - multiple
850		bacterial strain model. <i>PLoS One</i> . 9 (2014), doi:10.1371/journal.pone.0100458.
851	42.	D. Bogaert, A. Van Belkum, M. Sluijter, A. Luijendijk, R. De Groot, H. C. Rümke, H. A.
852		Verbrugh, P. W. M. Hermans, Colonisation by Streptococcus pneumoniae and
853		Staphylococcus aureus in healthy children. Lancet. 363, 1871–1872 (2004).
854	43.	D. M. Weinberger, V. E. Pitzer, G. Regev-Yochay, N. Givon-Lavi, R. Dagan,
855		Association between the Decline in Pneumococcal Disease in Unimmunized

856		Adults and Vaccine-Derived Protection Against Colonization in Toddlers and
857		Preschool-Aged Children. <i>Am. J. Epidemiol.</i> 188 , 160–168 (2019).
858	44.	D. I. Andersson, The biological cost of mutational antibiotic resistance: any
859		practical conclusions? <i>Curr. Opin. Microbiol.</i> 9 (2006), pp. 461–465.
860	45.	D. I. Andersson, D. Hughes, Antibiotic resistance and its cost: Is it possible to
861		reverse resistance? <i>Nat. Rev. Microbiol.</i> 8 , 260–271 (2010).
862	46.	C. Tedijanto, S. Olesen, Y. Grad, M. Lipsitch, Estimating the proportion of
863		bystander selection for antibiotic resistance among potentially pathogenic
864		bacterial flora. <i>Proc Natl Acad Sci USA</i> . 115 , E11988–E11995 (2018).
865	47.	L. Högberg, P. Geli, H. Ringberg, E. Melander, M. Lipsitch, K. Ekdahl, Age- and
866		serogroup-related differences in observed durations of nasopharyngeal carriage
867		of penicillin-resistant pneumococci. J. Clin. Microbiol. 45 , 948–952 (2007).
868	48.	A. Melegaro, N. J. Gay, G. F. Medley, Estimating the transmission parameters of
869		pneumococcal carriage in households. <i>Epidemiol. Infect.</i> 132 , 433–441 (2004).
870	49.	S. Cobey, M. Lipsitch, Niche and neutral effects of acquired immunity permit
871		coexistence of pneumococcal serotypes. Science (80). 335, 1376–1380 (2012).
872	50.	R. Malley, P. W. Anderson, Serotype-independent pneumococcal experimental
873		vaccines that induce cellular as well as humoral immunity. Proc. Natl. Acad. Sci. U.
874		<i>S. A.</i> 109 , 3623–3627 (2012).
875	51.	S. P. Jochems, J. N. Weiser, R. Malley, D. M. Ferreira, The immunological
876		mechanisms that control pneumococcal carriage. <i>PLoS Pathog.</i> 13 , 1–14 (2017).
877	52.	UK Department of Health and Social Care, "Tackling antimicrobial resistance 2019
878		to 2024: the UK's 5-year national action plan" (2019), (available at
879		https://www.gov.uk/government/publications/uk-5-year-action-plan-for-
880		antimicrobial-resistance-2019-to-2024).
881	53.	B. S. Buckley, N. Henschke, H. Bergman, B. Skidmore, E. J. Klemm, G. Villanueva, C.
882		Garritty, M. Paul, Impact of vaccination on antibiotic usage: a systematic review
883		and meta-analysis. Clin. Microbiol. Infect. In press (2019),
884		doi:10.1016/j.cmi.2019.06.030.
885	54.	A. Von Gottberg, L. De Gouveia, S. Tempia, V. Quan, S. Meiring, C. Von Mollendorf,
886		S. A. Madhi, E. R. Zell, M. Stat, J. R. Verani, K. L. O'Brien, C. G. Whitney, K. P.
887		Klugman, C. Cohen, Effects of vaccination on invasive pneumococcal disease in
888		South Africa. <i>N. Engl. J. Med.</i> 371 , 1889–1899 (2014).

889 A. Cassini, L. D. Högberg, D. Plachouras, A. Quattrocchi, A. Hoxha, G. S. Simonsen, 55. 890 M. Colomb-Cotinat, M. E. Kretzschmar, B. Devleesschauwer, M. Cecchini, D. A. 891 Ouakrim, T. C. Oliveira, M. J. Struelens, C. Suetens, D. L. Monnet, R. Strauss, K. 892 Mertens, T. Struyf, B. Catry, K. Latour, I. N. Ivanov, E. G. Dobreva, A. Tambic 893 Andraševic, S. Soprek, A. Budimir, N. Paphitou, H. Žemlicková, S. Schytte Olsen, U. 894 Wolff Sönksen, P. Märtin, M. Ivanova, O. Lyvtikäinen, J. Jalava, B. Coignard, T. Eckmanns, M. Abu Sin, S. Haller, G. L. Daikos, A. Gikas, S. Tsiodras, F. Kontopidou, 895 896 Á. Tóth, Á. Hajdu, Ó. Guólaugsson, K. G. Kristinsson, S. Murchan, K. Burns, P. 897 Pezzotti, C. Gagliotti, U. Dumpis, A. Liuimiene, M. Perrin, M. A. Borg, S. C. de Greeff, 898 J. C. Monen, M. B. Koek, P. Elstrøm, D. Zabicka, A. Deptula, W. Hryniewicz, M. 899 Caniça, P. J. Nogueira, P. A. Fernandes, V. Manageiro, G. A. Popescu, R. I. Serban, E. 900 Schréterová, S. Litvová, M. Štefkovicová, J. Kolman, I. Klavs, A. Korošec, B. Aracil, A. 901 Asensio, M. Pérez-Vázquez, H. Billström, S. Larsson, J. S. Reilly, A. Johnson, S. 902 Hopkins, Attributable deaths and disability-adjusted life-years caused by 903 infections with antibiotic-resistant bacteria in the EU and the European Economic 904 Area in 2015: a population-level modelling analysis. Lancet Infect. Dis. 19, 56–66 905 (2019). 906 56. M. Kobayashi, L. M. Conklin, G. Bigogo, G. Jagero, L. Hampton, K. E. Fleming-Dutra, 907 M. Junghae, M. da G. Carvalho, F. Pimenta, B. Beall, T. Taylor, K. F. Laserson, J. 908 Vulule, C. Van Beneden, L. Kim, D. R. Feikin, C. G. Whitney, R. F. Breiman, 909 Pneumococcal carriage and antibiotic susceptibility patterns from two cross-910 sectional colonization surveys among children aged <5 years prior to the 911 introduction of 10-valent pneumococcal conjugate vaccine - Kenya, 2009-2010. 912 BMC Infect. Dis. 17, 1–12 (2017). 913 57. M. Lipsitch, O. Abdullahi, A. D'Amour, W. Xie, D. M. Weinberger, E. Tchetgen 914 Tchetgen, J. A. G. Scott, Estimating rates of carriage acquisition and clearance and 915 competitive ability for pneumococcal serotypes in Kenya with a Markov 916 transition model. *Epidemiology*. 23, 510–519 (2012). 917 58. I. Rudan, K. L. O'Brien, H. Nair, L. Liu, E. Theodoratou, S. Qazi, I. Luksic, C. L. F. Walker, R. E. Black, H. Campbell, Child Health Epidemiology Reference Group, 918 919 Epidemiology and etiology of childhood pneumonia in 2010: estimates of 920 incidence, severe morbidity, mortality, underlying risk factors and causative 921 pathogens for 192 countries. J. Glob. Health. 3, S114-010401 (2013).


922	59.	A. N. Torné, J. G. Dias, C. Quinten, F. Hruba, M. C. Busana, P. L. Lopalco, A. J. A.
923		Gauci, L. Pastore-Celentano, M. Sabbe, J. Verhaegen, M. Koliou, D. Pieridou-
924		Bagkatzouni, P. Křižovà, J. Kozakova, J. Motlova, P. Valentiner-Branth, L.
925		Lambertsen, T. Georgakopoulou, H. Humphreys, T. Melillo, P. Caruana, M. Knol, H.
926		de Merkel, K. Elberse, D. Frimann, A. Skoczynska, W. Hryniewicz, A. Kuch, I.
927		Paradowska-Stankiewicz, M. Pana, M. Vitek, V. Učakar, B. H. Normark, T. Lepp, M.
928		Slack, P. A. Waight, European enhanced surveillance of invasive pneumococcal
929		disease in 2010: Data from 26 European countries in the post-heptavalent
930		conjugate vaccine era. <i>Vaccine</i> . 32 , 3644–3650 (2014).
931	60.	M. Tin Tin Htar, D. Christopoulou, H. J. Schmitt, Pneumococcal serotype evolution
932		in Western Europe. BMC Infect. Dis. 15, 1–10 (2015).
933	61.	B. Simell, K. Auranen, H. Käyhty, D. Goldblatt, R. Dagan, K. L. O'Brien, The
934		fundamental link between pneumococcal carriage and disease. Expert Rev.
935		Vaccines. 11 , 841–855 (2012).
936	62.	S. Flasche, A. Guilder, Using a mathematical model to assess the potential effects
937		of a new vaccine approach that targets enhanced clearance of pneumococcal
938		carriage. (2018).
939	63.	M. C. Negri, M. Lipsitch, J. Blázquez, B. R. Levin, F. Baquero, Concentration-
940		dependent selection of small phenotypic differences in TEM beta-lactamase-
941		mediated antibiotic resistance. Antimicrob. Agents Chemother. 44, 2485–91
942		(2000).
943	64.	A. R. Wargo, S. Huijben, J. C. de Roode, J. Shepherd, A. F. Read, Competitive release
944		and facilitation of drug-resistant parasites after therapeutic chemotherapy in a
945		rodent malaria model. <i>Proc. Natl. Acad. Sci.</i> 104 , 19914–19919 (2007).
946	65.	N. Wale, D. G. Sim, M. J. Jones, R. Salathe, T. Day, A. F. Read, Resource limitation
947		prevents the emergence of drug resistance by intensifying within-host
948		competition. Proc. Natl. Acad. Sci., 201715874 (2017).
949	66.	J. A. Lewnard, P. A. Tähtinen, M. K. Laine, L. Lindholm, J. Jalava, P. Huovinen, M.
950		Lipsitch, A. Ruohola, Impact of antimicrobial treatment for acute otitis media on
951		carriage dynamics of penicillin-susceptible and penicillin–non-susceptible
952		Streptococcus pneumoniae. J. Infect. Dis., jiy343 (2018).
953	67.	M. Filippini, G. Masiero, K. Moschetti, Socioeconomic determinants of regional
954		differences in outpatient antibiotic consumption: Evidence from Switzerland.

955		Health Policy (New. York). 78 , 77–92 (2006).
956	68.	D. Koller, F. Hoffmann, W. Maier, K. Tholen, R. Windt, G. Glaeske, Variation in
957		antibiotic prescriptions: Is area deprivation an explanation? Analysis of 1.2
958		million children in Germany. Infection. 41, 121–127 (2013).
959	69.	M. Di Martino, A. Lallo, U. Kirchmayer, M. Davoli, D. Fusco, Prevalence of antibiotic
960		prescription in pediatric outpatients in Italy: The role of local health districts and
961		primary care physicians in determining variation. A multilevel design for
962		healthcare decision support. <i>BMC Public Health</i> . 17 , 1–8 (2017).
963	70.	M. C. Goossens, B. Catry, J. Verhaegen, Antimicrobial resistance to benzylpenicillin
964		in invasive pneumococcal disease in Belgium, 2003-2010: The effect of altering
965		clinical breakpoints. <i>Epidemiol. Infect.</i> 141, 490–495 (2013).
966	71.	S. Cobey, E. B. Baskerville, C. Colijn, W. Hanage, C. Fraser, M. Lipsitch, Host
967		population structure and treatment frequency maintain balancing selection on
968		drug resistance. J. R. Soc. Interface. 14, 20170295 (2017).
969	72.	C. Ter Braak, A Markov Chain Monte Carlo version of the genetic algorithm
970		Differential Evolution: Easy Bayesian computing for real parameter spaces. Stat.
971		<i>Comput.</i> 16 , 239–249 (2006).
972	73.	T. Smieszek, K. B. Pouwels, F. C. K. Dolk, D. R. M. Smith, S. Hopkins, M. Sharland, A.
973		D. Hay, M. V Moore, J. V Robotham, Potential for reducing inappropriate antibiotic
974		prescribing in English primary care. J. Antimicrob. Chemother. 73 , ii36–ii43
975		(2018).
976		

977	Acknowledgements
978	
979	N.G.D., M.J. and K.E.A. were funded by the National Institute for Health Research Health
980	Protection Research Unit in Immunisation at the London School of Hygiene and Tropical
981	Medicine in partnership with Public Health England. The views expressed are those of
982	the authors and not necessarily those of the NHS, National Institute for Health Research,
983	Department of Health or Public Health England. S.F. was supported by a Sir Henry Dale
984	Fellowship jointly funded by the Wellcome Trust and Royal Society (grant number
985	208812/Z/17/Z).

Table 1. Mechanisms for maintaining coexistence


	Mechanism	Mode of action	Plausible mechanism for coexistence in <i>S. pneumoniae</i> ?	Consistent with empirical patterns?	
	Treatment diversity	Assortatively-mixing subpopulations differ in treatment rates (25, 34–37)	Ves Yes	Ves	
	Pathogen diversity	Subtypes maintained by diversifying selection differ in propensity for resistance (<i>38</i>)	Ves Yes	Ves Yes	
	Treated class	Individuals currently in treatment maintain resistant strains (<i>25, 34, 39, 40</i>)	No: Only supports a small amount of coexistence (25)	N/A	
DIVERSITY	Within-host niches	Sensitive and resistant strains exploit separate niches within the host (30, 41)	No: Resistant and sensitive strains are known to occupy the same niches (29)	N/A	
IQ	Mutation pressure	Mutation-selection balance maintains intermediate resistance frequency (<i>30, 31,</i> <i>37</i>)	No: De novo acquisition of resistance in <i>S. pneumoniae</i> is not frequent enough (<i>25</i>)	N/A	
	Prescription feedback	Doctors reduce prescribing of a drug as resistance to it increases (37, 39)	No: Does not explain how coexistence is maintained over a range of treatment rates	N/A	
Z	Within-host competition: Treatment competition	Within-host competition creates frequency-dependent selection for resistance (25, 26, 32, 33, 40)	Ves Yes	Ves Yes	
COMPETITION	Within-host competition: Growth competition	u	Ves	Ves	
00	Superinfection	Superinfection creates frequency-dependent selection for resistance (30)	No: Requires resistant strain to transmit better than sensitive strain in absence of antibiotics	N/A	



988

989 990 Fig. 1. Four models of resistance evolution. X hosts are uncolonised, S hosts are 991 colonised with the sensitive strain and R hosts are colonised with the resistant strain. λ_s and $\lambda_{\rm R}$ are the force of infection of the sensitive and resistant strain, respectively; *c* is 992 993 the transmission cost of resistance; *u* is the natural clearance rate; and τ is the rate of 994 antibiotic treatment. (a) "Treatment diversity": each country is split into subpopulations varying in treatment rate τ_i . Assortative mixing between 995 subpopulations maintains coexistence. (b) "Pathogen diversity": the pathogen comes in 996 997 multiple subtypes maintained by diversifying selection, each with its own clearance rate 998 u_d . Subtypes with a longer carriage duration experience stronger selection for 999 resistance than those with a shorter carriage duration, which maintains circulation of both sensitive and resistant strains overall. (c) "Treatment competition": singly-1000 1001 colonised hosts can acquire a small amount of another strain at relative rate k (host states S_R and R_S). Population-level coexistence is maintained by treatment-mediated 1002 within-host competition between co-colonising strains. (d) "Growth competition": as in 1003 (c), but the transmission cost of resistance is removed and sensitive strains now 1004 1005 outgrow resistant strains within co-colonised hosts at rate *b*. Coexistence is maintained 1006 by both treatment-mediated and growth-mediated within-host competition.

bioRxiv preprint doi: https://doi.org/10.1101/610188; this version posted October 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.



1007

1008

1009 **Fig 2. Four models reproduce patterns of resistance in** *S. pneumoniae* **in Europe**.

1010 **(a)** Model fits with associated WAIC (± standard error). Vertical lines show the 95%


1011 highest density intervals (HDIs) for the reported proportion of invasive *S. pneumoniae*

1012 isolates that are resistant to penicillin plotted against the penicillin consumption rate in

under-5s. Ribbons show the 50% and 95% HDIs for resistance prevalence from each
fitted model. (b) The top row shows estimated posterior distributions for the free

1015 parameters in each model; the bottom row shows model outputs associated with these

1016 parameters to aid interpretation.




1017 1018

1019 Fig. 3. Impact of interventions. Impact of vaccine and treatment interventions on (a)


1020 carriage prevalence, (b) resistance frequency, and (c) resistant carriage (mean and
1021 95% HDI). (d) Illustration of the strongest forces selecting for greater or lesser

1022 resistance across models.






1025 Fig. 4. Policy considerations. (a) Median equivalent reduction in prescribing across 1026 four models of resistance evolution, in terms of vaccine efficacy at reducing the 1027 prevalence of resistant pneumococcal carriage. This demonstrates the vaccine efficacy required to achieve a similar decrease in resistant carriage to a given reduction in 1028 antibiotic prescription rates. The impact on overall pneumococcal carriage is not 1029 considered here. The shaded bar shows an 8.8–23.1% reduction in prescriptions, an 1030 1031 estimate of the percentage of prescriptions which are clinically inappropriate in the UK (73). The dashed line shows a 15% reduction in prescriptions, which has recently been 1032 announced as a target by the UK government (52). (b) The full impact of vaccination, 1033 illustrated here with 30% vaccine efficacy, can take 5-20 years to play out (mean and 1034 1035 95% HDI). (c) Per-country impact of vaccination at 30% efficacy. Countries reporting to ECDC are ordered from lowest (NL) to highest (CY) reported rate of penicillin 1036 1037 consumption. Diamonds show the estimated change in all pneumococcal pneumonia 1038 cases, while filled distributions show the change in resistant cases.



- 1039
- 1040
- 1041 **Fig. 5. Vaccine impact in a high-burden setting.** Adjusting fitted models to be
- 1042 consistent with a high-burden setting yields different predictions for vaccine impact,
- 1043 highlighting both increased challenges and greater opportunities for resistance
- 1044 management via vaccination.





1047 **Fig 6. Explaining additional between-country variation in resistance frequency.**

1048 Allowing model parameters to vary across countries captures additional between-

1049 country variation in resistance frequency not captured by variation in the treatment

1050 rate. For example, (a) allowing the transmission rate β to vary across countries can

1051 explain the variation in some but not all models. **(b)** Depending upon which parameter

1052 is allowed to vary, models differ in how well they explain all additional between-

1053 country variation, with a clear separation (dashed line) between flexible and inflexible


1054 models. **(c)** Model-specific predictions for the impact of vaccination among those


1055 parameters that do fully capture the observed variation remain similar. Solid grey lines


show "base" model; dashed lines correspond with colours in panel b.

1057	Supplementary Materials for
1058	
1059	Competition and diversity determine vaccine impact
1060	on antibiotic resistance evolution
1061	
1062	Nicholas G. Davies, Stefan Flasche, Mark Jit, Katherine E. Atkins

1063	Supplementary Tables 1–7
1064	
1065	These tables can be found in an Excel spreadsheet accompanying the article.
1066	
1067	Literature review — Details of the literature review used to identify mechanisms for
1068	maintaining coexistence between sensitive and resistant bacterial strains.
1069	
1070	Summary of model parameters — Table describing model parameters and assumed
1071	values or prior distributions for model fitting.
1072	
1073	<i>Carriage duration</i> — Calculation of mean pneumococcal carriage duration for children
1074	under 5 years old in European settings.
1075	
1076	Penicillin consumption — Calculation of the mean number of defined daily doses of
1077	penicillin corresponding to a single treatment course for children under 5 years old in
1078	European countries.
1079	
1080	Pneumococcal morbidity — Calculation of the annual number of pneumococcal
1081	pneumonia cases in children under 5 in Europe and Kenya.
1082	
1083	<i>Carriage duration (Kilifi)</i> — Calculation of mean pneumococcal carriage duration for
1084	children under 5 years old in Kilifi, Kenya.
1085	
1086	MCMC diagnostics — Widely Applicable Information Criteria (WAIC), Leave-One-Out
1087	Information Criteria (LOOIC), effective posterior sample size and Gelman-Rubin
1088	diagnostics for Bayesian inference model fitting using Markov chain Monte Carlo.







1098


1099 **Supplementary Fig. 2.** Distribution of carriage prevalence and resistance frequency in

1100 the "Pathogen diversity" model. This verifies that the D-types with the highest

1101 prevalence of carriage (averaged over all countries, above) also exhibit the highest

1102 resistance frequency (separated by country, below), and shows that at equilibrium, D-


1103 types can exhibit intermediate frequencies of resistance.




allowing one parameter to vary between countries. Parameters *c* and *z* can capture the

1108 additional variation in resistance frequency between countries.

1104 1105




- 1111 **Supplementary Fig. 4.** Maximum *a posteriori* fits for the "Pathogen diversity" model
- allowing one parameter to vary between countries. Parameters *c*, δ , and *z* can capture
- 1113 the additional variation in resistance frequency between countries.



1114

1116 **Supplementary Fig. 5.** Maximum *a posteriori* fits for the "Treatment competition"

- 1117 model allowing one parameter to vary between countries. Parameters β , *c*, *u*, *k*, and *z*
- 1118 can capture the additional variation in resistance frequency between countries.




1121Supplementary Fig. 6. Maximum *a posteriori* fits for the "Growth competition" model1122allowing one parameter to vary between countries. Parameters *b* and *z* can capture the

additional variation in resistance frequency between countries.

1119

Treatment diversity




1124

1126 **Supplementary Fig. 7.** Impact of vaccination under the "Treatment diversity" model,

- 1127 for those parameters able to capture the between-country variation in resistance
- 1128 frequency. The base model fit (thick grey solid line) is compared with the model fits in
- 1129 which parameters vary between countries (thin dashed lines).

Pathogen diversity




1130

1132 **Supplementary Fig. 8.** Impact of vaccination under the "Pathogen diversity" model, for

- 1133 those parameters able to capture the between-country variation in resistance
- 1134 frequency. The base model fit (thick grey solid line) is compared with the model fits in
- 1135 which parameters vary between countries (thin dashed lines).


Treatment competition



1136

- 1138 Supplementary Fig. 9. Impact of vaccination under the "Treatment competition"
- 1139 model, for those parameters able to capture the between-country variation in resistance
- 1140 frequency. The base model fit (thick grey solid line) is compared with the model fits in
- 1141 which parameters vary between countries (thin dashed lines).

Growth competition




1142

1144 **Supplementary Fig. 10.** Impact of vaccination under the "Growth competition" model,

- 1145 for those parameters able to capture the between-country variation in resistance
- 1146 frequency. The base model fit (thick grey solid line) is compared with the model fits in
- 1147 which parameters vary between countries (thin dashed lines).

Treatment diversity




- 1148
- 1149

1150 **Supplementary Fig. 11.** Impact of vaccination under the "Treatment diversity" model,

- 1151 for those parameters *not* able to capture the between-country variation in resistance
- 1152 frequency. The base model fit (thick grey solid line) is compared with the model fits in
- 1153 which parameters vary between countries (thin dashed lines).

Pathogen diversity



1154

1155


1156 **Supplementary Fig. 12.** Impact of vaccination under the "Pathogen diversity" model,

1157 for those parameters *not* able to capture the between-country variation in resistance

1158 frequency. The base model fit (thick grey solid line) is compared with the model fits in

1159 which parameters vary between countries (thin dashed lines).

Treatment competition



1160

1161


1162 **Supplementary Fig. 13.** Impact of vaccination under the "Treatment competition"

1163 model, for those parameters *not* able to capture the between-country variation in

resistance frequency. The base model fit (thick grey solid line) is compared with the

1165 model fits in which parameters vary between countries (thin dashed lines).

Growth competition



1166

1168 **Supplementary Fig. 14.** Impact of vaccination under the "Growth competition" model,

- 1169 for those parameters *not* able to capture the between-country variation in resistance
- 1170 frequency. The base model fit (thick grey solid line) is compared with the model fits in
- 1171 which parameters vary between countries (thin dashed lines).